Objetive: The objective of this paper is to analyze the equity on the financing and access to medication in Mexico, in a context of growth in the market of t generic drugs. It also shows the level of prices and costs of diabetes treatment. Materials and Methods:This study is based on the national survey about the income and expense of households from 1998 and 2010. The Heckman model was used. This type of model has two stages: the first estimates the probability that the household make an expense on medications, while the second stage uses an Engel Curve model to explain the budgetary allocation of drug spending. Results:The poorest households without social security have an expense in medication relatively higher than the rest of the population. The cost of diabetes treatment with drugs without patent is too high. According to the results if the drug spending of a household income increases by 100% it is reduced by 11.79% in 1998, while in 2010 it drops in 11.59%. The estimation of this demand equation according to the theory of the consumer indicates that the introduction of generic drugs has brought a wealth effect since 2010 households consume more medication, just as predicted. Conclusion:The benefits of access to medicines may not be available on an equitable way. The poor households may not have the opportunity to achieve good health when it is affected by a disease which requires expensive medications or has a lifetime treatment and a great part of the household income is destined to it which makes them become poorer; this has a negative impact on social justice.

No abstract